| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 94 | 7.1x | 17.8x | Top tier | |
Growth | 66 | 10.0% | 7.1% | Around median | |
Quality | 82 | 12.3% | 4.5% | Top tier | |
Safety | 66 | 2.2x | 2.6x | Top tier | |
Capital Return | 31 | 0.44% | 2.12% | Bottom tier | |
Momentum | 29 | -6.5% | 2.9% | Bottom tier | |
Sentiment | 68 | 11 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Universal Health Services operates a healthcare network that combines acute care hospitals and behavioral health facilities, generating revenue from inpatient, emergency, surgical, and inpatient and outpatient behavioral treatment services. The company is expanding its model through freestanding emergency departments, ambulatory surgery centers, and Thousand Branches clinics, while the Talkspace transaction, which management expected to close in mid-August 2026 according to the July 28, 2026 call, aims to add nationwide virtual behavioral therapy services to in-person care.
In Q2 fiscal 2026, revenue was $4.6 billion, net income was $358.4 million, and adjusted earnings per share were $5.98, compared with revenue of $4.5 billion and net income of $348.7 million in Q1 fiscal 2026. Net income was equivalent to approximately 7.8% of revenue, while adjusted EBITDA net of noncontrolling interests was $678 million, representing annual growth of 5%, and adjusted earnings per share rose 12% year over year.
Operating growth came from both core segments: same-facility acute care revenue increased 8.2% and segment EBITDA rose 8.2%, while same-facility behavioral health revenue increased 7.4% and segment EBITDA rose 9.0%. However, the quarter's results included a $100 million benefit from the Florida DPP program related to a prior period; excluding it, management said adjusted EBITDA net of noncontrolling interests fell short of its internal expectations because of approximately $63 million in liability reserves and losses at the San Antonio and Cedar Hill facilities.
The analyst consensus on UHS is "Neutral," with an average target of $193 and a wide range of $166 to $290; the average is below the 52-week range high of $246.33, while the highest target exceeds that high. No price-to-earnings ratio is available in the provided data, so the valuation remains governed by the divergence among targets and the balance between expected earnings-per-share growth of approximately 6% in fiscal 2026 and the reduced EBITDA outlook, liability pressures, new facilities, and supplemental funding.
Figures in the text are as of 2026-08-29; the live price is shown at the top of the page.
Revenue was $4.6 billion and net income was $358.4 million in Q2 fiscal 2026, with adjusted earnings per share of $5.98. Adjusted earnings per share rose 12% year over year, and adjusted EBITDA net of noncontrolling interests was $678 million, up 5%. The results included a $100 million benefit from the Florida DPP program related to a prior period, and management said performance excluding this benefit fell short of its internal expectations.
In Q2 fiscal 2026, same-facility acute care revenue increased 8.2% and segment EBITDA rose 8.2%. In behavioral health, same-facility revenue increased 7.4% and EBITDA rose 9.0%. Acute care volumes were stronger, with adjusted admissions growing 2.9%, compared with 1.4% growth in adjusted behavioral health patient days.
According to the July 28, 2026 call, UHS expected the pending acquisition of Talkspace to close in mid-August 2026. Talkspace has a network of more than 6,000 therapists, providing a nationwide virtual option that was not previously available to UHS at the same scale. The company aims to use this capability to follow up with behavioral health patients after discharge from inpatient care when distance or limited therapist availability impedes access to in-person therapy.
Automated analysis for informational purposes only — not investment advice.
The company reduced the midpoint of its adjusted EBITDA net of noncontrolling interests outlook by approximately $50 million to $2.66 billion, within a new range of $2.61 billion to $2.72 billion. An additional benefit of approximately $150 million from Medicaid programs offset part of approximately $200 million in negative items not originally included, including the San Antonio facility, Cedar Hill's slower ramp-up, higher liability reserves, and lower volume assumptions. Nevertheless, at the midpoint, the outlook still indicates revenue growth of 7%, EBITDA growth of 3%, and earnings-per-share growth of 6% in fiscal 2026.
The facility stopped receiving reimbursements from government and commercial sources at the end of April 2026 during the reaccreditation process. Its pretax losses were approximately $10 million in Q2 fiscal 2026, including employee termination costs, and UHS expects operating losses of $5 million to $10 million per quarter during the remainder of fiscal 2026. The facility generated approximately $25 million in EBITDA during fiscal 2025, and the company expects accreditation to be restored in 2027 without specifying a final date or conditions.
Operations generated $44.3 million in cash in Q2 fiscal 2026, down from $549 million in the corresponding period, while capital expenditures were $228 million. On June 30, 2026, the company had $139 million in cash, $4.85 billion of debt, and net leverage of 1.8 times, along with $1.27 billion of available borrowing capacity. It also repurchased 1.89 million shares for $320 million during the quarter, with $978 million remaining under the repurchase authorization.
